KEAP1 and diabetic retinopathy: Besides its validated activity as tyrosine kinase receptor inhibitor, we found in our in vitro models of diabetic retinopathy that axitinib exerts antioxidant, anti-inflammatory and anti-angiogenic effects, also regulating Nrf2 expression, likely through covalent binding to Keap1-BTB domain.